Breaking Down the Science: The T1D and COVID-19 Surveillance Study
In March of 2020, T1D Exchange quickly recognized — along with the rest of the country — that COVID-19 was…
Vertex Pharmaceuticals Pursues Investigational Cell Therapies for Type 1 Diabetes
In the fall of 2019, Vertex Pharmaceuticals Incorporated acquired Semma Therapeutics for $950 million. Founded by Douglas Melton, Ph.D. and…
All About The T1D Exchange Quality Improvement Collaborative (QIC)
Providing supportive care for those living with T1D is complex and comes with an ongoing responsibility of knowing how to…
Chatting with Dexcom CEO About the New G7, the Sampling Program, and the Patient Voice
There are approximately 900,000 people across the globe wearing a Dexcom continuous glucose monitor (CGM) today. “Up from 600,000 at…
Evaluating Telemedicine: Connecting Patient Voice to Research
While “telemedicine” certainly existed prior to the COVID-19 pandemic, it was simply an option for patients who preferred it or…
Mental Health in T1D: How the T1D Exchange Quality Improvement Collaborative is Changing Patient Care
Just as there is no “one-size-fits-all” insulin dosing regimen in type 1 diabetes, there are an endless variety of ways…
